Integra LifeSciences Holdings (IART) 2021年年度报告「NASDAQ」.pdf

1、2021 Annual ReportTO OUR SHAREHOLDERSBy all measures,2021 was a successful year for Integra LifeSciences.Throughout this unpredictable time,Integra colleagues showed tremendous resilience and perseverance in serving our customers and patients,and in moving our company forward.Our manufacturing facil

2、ities remained operational,producing life-saving products and technologies.Our field sales teams continued to ramp up customer visits to support health care providers as surgical procedures resumed.Most importantly,colleagues around the world stayed true to our mission and values and put our custome

3、rs and patients first.Our success last year would not have been possible if not for the outstanding contributions of our 3,700 colleagues around the globe.“Throughout this unpredictable time,Integra colleagues showed tremendous resilience and perseverance in serving our customers and patients.”In 20

4、21,our full-year revenues were more than$1.54 billion,with organic growth exceeding 14%compared to 2020,and 4.6%compared to 2019.We saw strong recovery across most of our product lines despite COVID-19 setbacks,a result of the critical nature of our products products and solutions that play a crucia

5、l role in improving the quality of peoples lives.Codman Specialty Surgical(CSS)revenues grew to$1.025 billion in 2021,representing 15%organic growth fueled by recovery in our neurosurgery and instruments businesses,as well as new product introductions.Our Tissue Technologies revenues were$517 millio

6、n,representing 12.6%organic growth.This increase was attributed to growth in sales in wound reconstruction,primarily led by Integra skin and SurgiMend products in our burn,trauma,and surgical reconstruction markets,as well as demand recovery in our private-label business.Additionally,the ACell busin